Ludlam C A, Tucker J, Steel C M, Tedder R S, Cheingsong-Popov R, Weiss R A, McClelland D B, Philp I, Prescott R J
Lancet. 1985 Aug 3;2(8449):233-6. doi: 10.1016/s0140-6736(85)90288-0.
Fifteen haemophiliac patients acquired antibodies to human T-lymphotropic virus type III during 1984. One batch of factor VIII concentrate given to all these patients is presumed to be the cause of the seroconversion. A further eighteen patients who received the same batch did not seroconvert and one other patient became seropositive but had not received this batch. Before transfusion of the implicated batch the patients had low T-helper-cell numbers and T-helper/suppressor ratios; neither changed in those who seroconverted. The probability of seroconversion was independently related to the pre-existing low T-helper/suppressor ratio, the number of vials of the implicated batch transfused, and the total annual factor VIII consumption. Ten other patients received a batch of factor IX concentrate from the same donor plasma; none of these patients seroconverted.
1984年，15名血友病患者感染了人类嗜T淋巴细胞病毒III型抗体。给所有这些患者使用的一批凝血因子VIII浓缩剂被认为是血清转化的原因。另外18名接受同一批次药物的患者未发生血清转化，另有一名患者血清呈阳性，但未接受该批次药物。在输注有问题的批次之前，患者的辅助性T细胞数量和辅助性T细胞/抑制性T细胞比值较低；发生血清转化的患者中这两项指标均未改变。血清转化的可能性与预先存在的低辅助性T细胞/抑制性T细胞比值、输注的有问题批次的瓶数以及每年凝血因子VIII的总消耗量独立相关。另外10名患者接受了来自同一供体血浆的一批凝血因子IX浓缩剂；这些患者均未发生血清转化。
